[en] Soluble glycoprotein VI (sGPVI) is shed from the platelet surface and is a marker of platelet activation in thrombotic conditions. We assessed sGPVI levels together with patient and clinical parameters in acute and chronic inflammatory conditions, including patients with thermal injury and inflammatory bowel disease and patients admitted to the intensive care unit (ICU) for elective cardiac surgery, trauma, acute brain injury, or prolonged ventilation. Plasma sGPVI was measured by enzyme-linked immunosorbent assay and was elevated on day 14 after thermal injury, and was higher in patients who developed sepsis. sGPVI levels were associated with sepsis, and the value for predicting sepsis was increased in combination with platelet count and Abbreviated Burn Severity Index. sGPVI levels positively correlated with levels of D-dimer (a fibrin degradation product) in ICU patients and patients with thermal injury. sGPVI levels in ICU patients at admission were significantly associated with 28- and 90-day mortality independent of platelet count. sGPVI levels in patients with thermal injury were associated with 28-day mortality at days 1, 14, and 21 when adjusting for platelet count. In both cohorts, sGPVI associations with mortality were stronger than D-dimer levels. Mechanistically, release of GPVI was triggered by exposure of platelets to polymerized fibrin, but not by engagement of G protein-coupled receptors by thrombin, adenosine 5'-diphosphate, or thromboxane mimetics. Enhanced fibrin production in these patients may therefore contribute to the observed elevated sGPVI levels. sGPVI is an important platelet-specific marker for platelet activation that predicts sepsis progression and mortality in injured patients.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Montague, Samantha ✱; Australian Cancer Research Foundation Department of Cancer Biology and Therapeutics, John Curtin School of Medical Research
Delierneux, Céline ✱; Department of Cellular and Molecular Physiology Pennsylvania State University College of Medicine
LECUT, Christelle ; Centre Hospitalier Universitaire de Liège - CHU > Unité de laboratoire - thrombose - hémostase
LAYIOS, Nathalie ; Centre Hospitalier Universitaire de Liège - CHU > Service des soins intensifs généraux
Dinsdale, RJ; Scar Free Foundation for Burns Research, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham National Health Service (NHS) Foundation Trust, Birmingham, United Kingdom
Lee, CS; Australian Cancer Research Foundation Department of Cancer Biology and Therapeutics, John Curtin School of Medical Research
Poulter, NS; Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom
Andrews, RK; Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia
Hampson, P; Scar Free Foundation for Burns Research, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham National Health Service (NHS) Foundation Trust, Birmingham, United Kingdom
Wearn, CM; Scar Free Foundation for Burns Research, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham National Health Service (NHS) Foundation Trust, Birmingham, United Kingdom
MAES, Nathalie ; Centre Hospitalier Universitaire de Liège - CHU > Secteur d'appui à la recherche clinique et biostatistique
Bishop, J; National Institute for Health Research Surgical Reconstruction and Microbiology Centre (Trauma Research), University of Birmingham, Birmingham
Bamford, A; Scar Free Foundation for Burns Research, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham National Health Service (NHS) Foundation Trust, Birmingham, United Kingdom
Gardiner, C; Department of Haematology, University College London, London,
Lee, WM; Australian Cancer Research Foundation Department of Cancer Biology and Therapeutics, John Curtin School of Medical Research
Iqbal, T; Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham
Moiemen, N; Scar Free Foundation for Burns Research, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham National Health Service (NHS) Foundation Trust, Birmingham, United Kingdom
Watson, SP; Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom
Oury, Cécile ✱; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > GIGA-R : GIGA - Cardiovascular Sciences
Harrisson, P ✱; Scar Free Foundation for Burns Research, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham National Health Service (NHS) Foundation Trust, Birmingham, United Kingdom
Gardiner, E ✱; Australian Cancer Research Foundation Department of Cancer Biology and Therapeutics, John Curtin School of Medical Research
Hayakawa M, Sawamura A, Gando S, et al. Disseminated intravascular coagulation at an early phase of trauma is associated with consumption coagulopathy and excessive fibrinolysis both by plasmin and neutrophil elastase. Surgery. 2011;149(2):221-230.
Frith D, Goslings JC, Gaarder C, et al. Definition and drivers of acute traumatic coagulopathy: clinical and experimental investigations. J Thromb Haemost. 2010;8(9):1919-1925.
Levi M, van der Poll T. Coagulation and sepsis. Thromb Res. 2017;149:38-44.
Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis-associated disseminated intravascular coagulation and thromboembolic disease. Mediterr J Hematol Infect Dis. 2010;2(3):e2010024.
Davis RP, Miller-Dorey S, Jenne CN. Platelets and coagulation in infection. Clin Transl Immunology. 2016;5(7):e89.
Mitra B, Cameron PA, Mori A, Fitzgerald M. Acute coagulopathy and early deaths post major trauma. Injury. 2012;43(1):22-25.
Winearls J, Campbell D, Hurn C, et al. Fibrinogen in traumatic haemorrhage: A narrative review. Injury. 2017;48(2):230-242.
Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma. 2003;54(6):1127-1130.
Hayakawa M. Pathophysiology of trauma-induced coagulopathy: disseminated intravascular coagulation with the fibrinolytic phenotype. J Intensive Care. 2017;5(14):14.
Alshehri OM, Hughes CE, Montague S, et al. Fibrin activates GPVI in human and mouse platelets. Blood. 2015;126(13):1601-1608.
Mammadova-Bach E, Ollivier V, Loyau S, et al. Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation. Blood. 2015; 126(5):683-691.
Clemetson JM, Polgar J, Magnenat E, Wells TN, Clemetson KJ. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcalphaR and the natural killer receptors. J Biol Chem. 1999;274(41):29019-29024.
Gibbins JM, Okuma M, Farndale R, Barnes M, Watson SP. Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor g-chain. FEBS Lett. 1997;413(2):255-259.
Jung SM, Moroi M, Soejima K, et al. Constitutive dimerization of glycoprotein VI (GPVI) in resting platelets is essential for binding to collagen and activation in flowing blood. J Biol Chem. 2012;287(35):30000-30013.
Loyau S, Dumont B, Ollivier V, et al. Platelet glycoprotein VI dimerization, an active process inducing receptor competence, is an indicator of platelet reactivity. Arterioscler Thromb Vasc Biol. 2012;32(3):778-785.
Poulter NS, Pollitt AY, Owen DM, et al. Clustering of glycoprotein VI (GPVI) dimers upon adhesion to collagen as a mechanism to regulate GPVI signaling in platelets. J Thromb Haemost. 2017;15(3):549-564.
Séverin S, Nash CA, Mori J, et al. Distinct and overlapping functional roles of Src family kinases in mouse platelets. J Thromb Haemost. 2012;10(8): 1631-1645.
Lee RH, Bergmeier W. Platelet immunoreceptor tyrosine-based activation motif (ITAM) and hemITAM signaling and vascular integrity in inflammation and development. J Thromb Haemost. 2016;14(4):645-654.
Boulaftali Y, Hess PR, Getz TM, et al. Platelet ITAM signaling is critical for vascular integrity in inflammation. J Clin Invest. 2013;123(2):908-916.
Gros A, Syvannarath V, Lamrani L, et al. Single platelets seal neutrophil-induced vascular breaches via GPVI during immune-complex-mediated inflammation in mice. Blood. 2015;126(8):1017-1026.
Qiao JL, Shen Y, Gardiner EE, Andrews RK. Proteolysis of platelet receptors in humans and other species. Biol Chem. 2010;391(8):893-900.
Gardiner EE, Arthur JF, Kahn ML, Berndt MC, Andrews RK. Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinase. Blood. 2004;104(12):3611-3617.
Bergmeier W, Rabie T, Strehl A, et al. GPVI down-regulation in murine platelets through metalloproteinase-dependent shedding. Thromb Haemost. 2004;91(5):951-958.
Rabie T, Varga-Szabo D, Bender M, et al. Diverging signaling events control the pathway of GPVI down-regulation in vivo. Blood. 2007;110(2):529-535.
Stephens G, Yan Y, Jandrot-Perrus M, Villeval JL, Clemetson KJ, Phillips DR. Platelet activation induces metalloproteinase-dependent GP VI cleavage to down-regulate platelet reactivity to collagen. Blood. 2005;105(1):186-191.
Wijeyewickrema LC, Gardiner EE, Moroi M, Berndt MC, Andrews RK. Snake venom metalloproteinases, crotarhagin and alborhagin, induce ectodomain shedding of the platelet collagen receptor, glycoprotein VI. Thromb Haemost. 2007;98(6):1285-1290.
Gitz E, Pollitt AY, Gitz-Francois JJ, et al. CLEC-2 expression is maintained on activated platelets and on platelet microparticles. Blood. 2014;124(14): 2262-2270.
Gardiner EE, Karunakaran D, Arthur JF, et al. Dual ITAM-mediated proteolytic pathways for irreversible inactivation of platelet receptors: de-ITAM-izing FcgammaRIIa. Blood. 2008;111(1):165-174.
Al-Tamimi M, Mu FT, Moroi M, Gardiner EE, Berndt MC, Andrews RK. Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets. 2009;20(3):143-149.
Bigalke B, Pötz O, Kremmer E, et al. Sandwich immunoassay for soluble glycoprotein VI in patients with symptomatic coronary artery disease. Clin Chem. 2011;57(6):898-904.
Yamashita Y, Naitoh K, Wada H, et al. Elevated plasma levels of soluble platelet glycoprotein VI (GPVI) in patients with thrombotic microangiopathy. Thromb Res. 2014;133(3):440-444.
Al-Tamimi M, Gardiner EE, Thom JY, et al. Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke. Stroke. 2011;42(2): 498-500.
Laske C, Leyhe T, Stransky E, et al. Association of platelet-derived soluble glycoprotein VI in plasma with Alzheimer's disease. J Psychiatr Res. 2008; 42(9):746-751.
Stack JR, Madigan A, Helbert L, et al. Soluble glycoprotein VI, a specific marker of platelet activation is increased in the plasma of subjects with seropositive rheumatoid arthritis. PLoS One. 2017;12(11):e0188027.
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-810.
Hampson P, Dinsdale RJ, Wearn CM, et al. Neutrophil dysfunction, immature granulocytes, and cell-free DNA are early biomarkers of sepsis in burninjured patients: a prospective observational cohort study. Ann Surg. 2017;265(6):1241-1249.
Dinsdale RJ, Devi A, Hampson P, et al. Changes in novel haematological parameters following thermal injury: A prospective observational cohort study. Sci Rep. 2017;7(1):3211.
Greenhalgh DG, Saffle JR.Holmes JH 4th, et al. American Burn Association consensus conference to define sepsis and infection in burns. J Burn Care Res. 2007;28(6):776-790.
Suzuki-Inoue K, Inoue O, Frampton J, Watson SP. Murine GPVI stimulates weak integrin activation in PLCgamma2-/-platelets: involvement of PLCgamma1 and PI3-kinase. Blood. 2003;102(4):1367-1373.
Bakhtiari K, Meijers JC, de Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med. 2004;32(12):2416-2421.
Marck RE, Montagne HL, Tuinebreijer WE, Breederveld RS. Time course of thrombocytes in burn patients and its predictive value for outcome. Burns. 2013;39(4):714-722.
Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA. 2014;311(13):1308-1316.
Fleischmann C, Scherag A, Adhikari NK, et al; International Forum of Acute Care Trialists. Assessment of global incidence and mortality of hospitaltreated sepsis. Current estimates and limitations. Am J Respir Crit Care Med. 2016;193(3):259-272.
Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707-710.
Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818-829.
Vincent JL, Mira JP, Antonelli M. Sepsis: older and newer concepts. Lancet Respir Med. 2016;4(3):237-240.
Reddi BA, Iannella SM, O'Connor SN, Deane AM, Willoughby SR, Wilson DP. Attenuated platelet aggregation in patients with septic shock is independent from the activity state of myosin light chain phosphorylation or a reduction in Rho kinase-dependent inhibition of myosin light chain phosphatase. Intensive Care Med Exp. 2015;3(1):37.
Yaguchi A, Lobo FL, Vincent JL, Pradier O. Platelet function in sepsis. J Thromb Haemost. 2004;2(12):2096-2102.
Katz JN, Kolappa KP, Becker RC. Beyond thrombosis: the versatile platelet in critical illness. Chest. 2011;139(3):658-668.
Zhang S, Cui YL, Diao MY, Chen DC, Lin ZF. Use of platelet indices for determining illness severity and predicting prognosis in critically ill patients. Chin Med J. 2015;128(15):2012-2018.
Layios N, Delierneux C, Hego A, et al. Sepsis prediction in critically ill patients by platelet activation markers on ICU admission: a prospective pilot study. Intensive Care Med Exp. 2017;5(1):32.
Qiao J, Schoenwaelder SM, Mason KD, et al. Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263). Blood. 2013;121(8):1479-1481.
Levin GY, Egorihina MN. The role of fibrinogen in aggregation of platelets in burn injury. Burns. 2010;36(6):806-810.
Guagnozzi D, Lucendo AJ. Anemia in inflammatory bowel disease: a neglected issue with relevant effects. World J Gastroenterol. 2014;20(13): 3542-3551.
Bergamaschi G, Di Sabatino A, Albertini R, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica. 2010;95(2):199-205.
Byrnes JR, Wolberg AS. Red blood cells in thrombosis. Blood. 2017;130(16):1795-1799.
Bender M, Hofmann S, Stegner D, et al. Differentially regulated GPVI ectodomain shedding by multiple platelet-expressed proteinases. Blood. 2010; 116(17):3347-3355.
Facey A, Pinar I, Arthur JF, et al. A-disintegrin-and-metalloproteinase (ADAM) 10 activity on resting and activated platelets. Biochemistry. 2016;55(8): 1187-1194.
Al-Tamimi M, Grigoriadis G, Tran H, et al. Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa. Blood. 2011;117(14): 3912-3920.
Al-Tamimi M, Tan CW, Qiao J, et al. Pathologic shear triggers shedding of vascular receptors: a novel mechanism for down-regulation of platelet glycoprotein VI in stenosed coronary vessels. Blood. 2012;119(18):4311-4320.
Lee MY, Verni CC, Herbig BA, Diamond SL. Soluble fibrin causes an acquired platelet glycoprotein VI signaling defect: implications for coagulopathy. J Thromb Haemost. 2017;15(12):2396-2407.
Onselaer M-B, Hardy AT, Wilson C, et al. Fibrin and D-dimer bind to monomeric GPVI. Blood Adv. 2017;1(19):1495-1504.
